Generated by AI
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company developing drug delivery systems and immuno-oncology therapies for difficult-to-treat liver and pancreatic cancers. Its current product portfolio centers on Pressure-Enabled Drug Delivery (PEDD) platforms, including the TriNav infusion system for hepatic arterial procedures and the Pancreatic Retrograde Venous Infusion device. TriSalus also advances nelitolimod, an investigational immunotherapeutic designed to work alongside standard treatments in solid tumors. The company’s products and clinical programs are aimed at improving how therapies reach tumor sites, particularly where conventional delivery faces anatomical and physiological barriers. TriSalus Life Sciences, Inc. serves the interventional oncology and medical device markets, combining device-based delivery with oncology therapeutics to support physicians treating liver cancer, liver metastases, and pancreatic tumors.
Website6272 West 91st Avenue
Westminster, CO, 80031
United States
The latest articles about TLSI.
TriSalus Life Sciences is back in focus as analysts reset their fair value estimate from US$10 to US$8.25, reflecting a meaningful shift in how current upside is being framed. These changes follow recent Q3 results and a guidance reset, with research updates balancing concern around execution with interest in the TriNav platform and future procedure growth. As you read on, you will see how to track these evolving views and what to watch next in the TriSalus Life Sciences story. Stay updated...
Summary of Sep 23's posts. Generated by AI.
No summary yet.
No summary yet.
No summary yet.
Summary of Sep 23's posts. Generated by AI.
Investors talking about TLSI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.